China Pharma Receives SFDA Approval For Rosuvastatin

China Pharma has received official approval from China’ State Food and Drug Administration (SFDA) to enter phase-I and phase-II clinical trials, to test the efficacy of cholesterol-lowering drug, Rosuvastatin.

The company plans to begin the trials soon, and estimates that it will receive a production license by the end of 2010.

Rosuvastatin is the generic version of Crestor that has shown to significantly reduce LDL cholesterol.

Zhilin Li, CEO and President, China Pharma, said: We are very pleased that the SFDA has approved China Pharma to pursue clinical trials for Rosuvastatin. We anticipate that Rosuvastatin will greatly help to meet the medical needs of Chinese patients suffering from hyperlipidemia and requiring medicine to control cholesterol.